Skip to main content
Top
Published in: Digestive Diseases and Sciences 6/2014

01-06-2014 | Editorial

Understanding New Concepts: Clostridium difficile Infection in Pouch Patients

Author: Grigoriy E. Gurvits

Published in: Digestive Diseases and Sciences | Issue 6/2014

Login to get access

Excerpt

Inflammatory bowel disease (IBD) is a major medical condition that affects nearly 1.5 million Americans, with over 70,000 new cases diagnosed annually. Over the last 50 years, rapid advances in the understanding of its pathophysiology and diagnosis, combined with the utilization of emerging medical therapies have better controlled the disease, have decreased morbidity, and have prolonged survival. Yet, the lifelong risk of surgery in patients with Crohn’s disease (CD) was traditionally reported at 75 % and with ulcerative colitis (UC) at 25 %, numbers likely to stay unchanged. One of the frequent operations performed for patients with these diseases is restorative proctocolectomy with ileal pouch anal anastomosis (IPAA), a procedure reserved for patients with advanced UC refractory to currently available medical therapy or who develop colonic dysplasia or cancer. First described in 1978 by Parks and Nicholls [1], this procedure truly revolutionized patient care in that it maintained gut continuity and avoided the need for permanent ileostomy in patients with UC. Over the years, with technical improvements, it has also become the procedure of choice for patients with familial adenomatous polyposis syndrome requiring colectomy. …
Literature
3.
go back to reference Li Y, Qian J, Queener E, Shen B. Risk factors and outcome of PCR-detected Clostridium difficile infection in ileal pouch patients. Inflamm Bowel Dis. 2013;19:397–403.PubMedCrossRef Li Y, Qian J, Queener E, Shen B. Risk factors and outcome of PCR-detected Clostridium difficile infection in ileal pouch patients. Inflamm Bowel Dis. 2013;19:397–403.PubMedCrossRef
4.
go back to reference Sun C, Du P, Wu XR, Queener E, Shen B. Preoperative Clostridium difficile infection is not associated with an increased risk for the infection in ileal pouch patients. Dig Dis Sci (Epub ahead of print). doi: 10.1007/s10620-014-3047-0. Sun C, Du P, Wu XR, Queener E, Shen B. Preoperative Clostridium difficile infection is not associated with an increased risk for the infection in ileal pouch patients. Dig Dis Sci (Epub ahead of print). doi: 10.​1007/​s10620-014-3047-0.
5.
go back to reference Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect. 2009;58:403–410.PubMedCrossRef Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect. 2009;58:403–410.PubMedCrossRef
6.
go back to reference Ananthakrishnan AN. Detecting and treating Clostridium difficile infections in patients with inflammatory bowel disease. Gastroenterol Clin North Am. 2012;41:339–353.PubMedCrossRef Ananthakrishnan AN. Detecting and treating Clostridium difficile infections in patients with inflammatory bowel disease. Gastroenterol Clin North Am. 2012;41:339–353.PubMedCrossRef
7.
go back to reference Eglow R, Pothoulakis C, Itzkowitz S, et al. Diminished Clostridium difficile toxin A sensitivity in newborn rabbit ileum is associated with decreased toxin A receptor. J Clin Invest. 1992;90:822–829.PubMedCentralPubMedCrossRef Eglow R, Pothoulakis C, Itzkowitz S, et al. Diminished Clostridium difficile toxin A sensitivity in newborn rabbit ileum is associated with decreased toxin A receptor. J Clin Invest. 1992;90:822–829.PubMedCentralPubMedCrossRef
8.
go back to reference Sammons JS, Toltzis P, Zaoutis TE. Clostridium difficile infection in children. JAMA Pediatr. 2013;167:567–573.PubMedCrossRef Sammons JS, Toltzis P, Zaoutis TE. Clostridium difficile infection in children. JAMA Pediatr. 2013;167:567–573.PubMedCrossRef
9.
go back to reference Garey KW, Sethi S, Yadav Y, DuPont HL. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect. 2008;70:298–304.PubMedCrossRef Garey KW, Sethi S, Yadav Y, DuPont HL. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect. 2008;70:298–304.PubMedCrossRef
10.
go back to reference Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile associated diarrhea. J Infect Dis. 2008;197:435–438.PubMedCrossRef Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile associated diarrhea. J Infect Dis. 2008;197:435–438.PubMedCrossRef
11.
go back to reference Ananthakrishnan AN, Binion DG. Impact of Clostridium difficile on inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2010;4:589–600.PubMedCrossRef Ananthakrishnan AN, Binion DG. Impact of Clostridium difficile on inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2010;4:589–600.PubMedCrossRef
Metadata
Title
Understanding New Concepts: Clostridium difficile Infection in Pouch Patients
Author
Grigoriy E. Gurvits
Publication date
01-06-2014
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 6/2014
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-014-3112-8

Other articles of this Issue 6/2014

Digestive Diseases and Sciences 6/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.